Alector (ALEC) Competitors $1.60 +0.02 (+0.94%) As of 12:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALEC vs. TNGX, PHAT, XNCR, IOVA, UPB, RLAY, CDXC, EOLS, MNMD, and ABUSShould you be buying Alector stock or one of its competitors? The main competitors of Alector include Tango Therapeutics (TNGX), Phathom Pharmaceuticals (PHAT), Xencor (XNCR), Iovance Biotherapeutics (IOVA), Upstream Bio (UPB), Relay Therapeutics (RLAY), ChromaDex (CDXC), Evolus (EOLS), Mind Medicine (MindMed) (MNMD), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Alector vs. Its Competitors Tango Therapeutics Phathom Pharmaceuticals Xencor Iovance Biotherapeutics Upstream Bio Relay Therapeutics ChromaDex Evolus Mind Medicine (MindMed) Arbutus Biopharma Tango Therapeutics (NASDAQ:TNGX) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation. Do analysts recommend TNGX or ALEC? Tango Therapeutics presently has a consensus price target of $10.50, indicating a potential upside of 58.47%. Alector has a consensus price target of $4.00, indicating a potential upside of 148.29%. Given Alector's higher probable upside, analysts plainly believe Alector is more favorable than Tango Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14 Do insiders & institutionals believe in TNGX or ALEC? 79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 7.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 9.1% of Alector shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor TNGX or ALEC? In the previous week, Tango Therapeutics had 2 more articles in the media than Alector. MarketBeat recorded 2 mentions for Tango Therapeutics and 0 mentions for Alector. Tango Therapeutics' average media sentiment score of 0.33 beat Alector's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tango Therapeutics Neutral Alector Neutral Is TNGX or ALEC more profitable? Alector has a net margin of -139.74% compared to Tango Therapeutics' net margin of -322.67%. Tango Therapeutics' return on equity of -62.75% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Tango Therapeutics-322.67% -62.75% -39.94% Alector -139.74%-100.58%-25.15% Which has stronger earnings and valuation, TNGX or ALEC? Alector has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTango Therapeutics$42.07M17.07-$130.30M-$1.22-5.43Alector$100.56M1.60-$119.05M-$1.26-1.28 Which has more volatility and risk, TNGX or ALEC? Tango Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. SummaryTango Therapeutics and Alector tied by winning 8 of the 16 factors compared between the two stocks. Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.98M$2.93B$5.51B$9.47BDividend YieldN/A2.48%4.00%4.04%P/E Ratio-1.2920.0028.1819.90Price / Sales1.60235.57426.8892.15Price / CashN/A40.8024.9928.17Price / Book1.257.768.275.77Net Income-$119.05M-$55.16M$3.24B$257.79M7 Day Performance-3.89%3.31%1.80%2.77%1 Month Performance9.18%15.60%9.32%14.17%1 Year Performance-72.47%5.92%35.12%20.71% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector3.5697 of 5 stars$1.61+1.3%$4.00+148.3%-72.7%$161.98M$100.56M-1.29270TNGXTango Therapeutics1.6226 of 5 stars$5.93-2.9%$12.20+105.7%-27.0%$642.78M$40.99M-4.8690PHATPhathom Pharmaceuticals4.1819 of 5 stars$9.18-5.3%$17.50+90.6%-27.4%$640.86M$55.25M-1.75110XNCRXencor4.1163 of 5 stars$8.83-4.8%$28.00+217.1%-53.1%$628.43M$110.49M-2.89280IOVAIovance Biotherapeutics4.6102 of 5 stars$1.87-3.1%$12.22+553.6%-72.0%$624.45M$164.07M-1.51500Analyst RevisionUPBUpstream BioN/A$11.48-3.0%$56.50+392.2%N/A$617.56M$2.30M0.0038RLAYRelay Therapeutics2.6695 of 5 stars$3.60-3.5%$17.67+390.7%-59.3%$617.22M$10.01M-1.61330Positive NewsCDXCChromaDexN/AN/A$9.03+∞N/A$611.50M$99.60M787.29120EOLSEvolus3.9988 of 5 stars$9.48-2.6%$23.75+150.5%-23.1%$611.27M$266.27M-10.65170Positive NewsMNMDMind Medicine (MindMed)1.6492 of 5 stars$8.06-0.5%$25.50+216.4%+12.0%$608.93MN/A-6.2540ABUSArbutus Biopharma1.5617 of 5 stars$3.17-3.4%$5.50+73.5%-15.2%$607.15M$6.17M-7.7390 Related Companies and Tools Related Companies Tango Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Xencor Alternatives Iovance Biotherapeutics Alternatives Upstream Bio Alternatives Relay Therapeutics Alternatives ChromaDex Alternatives Evolus Alternatives Mind Medicine (MindMed) Alternatives Arbutus Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALEC) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
